Loading clinical trials...
Loading clinical trials...
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS014004 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University of California, San Diego
San Diego, California, United States
Sarah Cannon Research Institute
Denver, Colorado, United States
Advent Health
Orlando, Florida, United States
Henry Ford Health Cancer
Detroit, Michigan, United States
NYU Langone Health
New York, New York, United States
The University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
NEXT Oncology, Virginia
Fairfax, Virginia, United States
Swedish Cancer Institute
Seattle, Washington, United States
BC Cancer Vancouver Centre
Vancouver, British Columbia, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Start Date
June 24, 2024
Primary Completion Date
April 1, 2027
Completion Date
October 1, 2027
Last Updated
March 13, 2026
63
ESTIMATED participants
ANS014004
DRUG
Lead Sponsor
Avistone Biotechnology Co., Ltd.
NCT06716138
NCT05581004
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions